A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks

被引：0

作者：

Smolen, Josef ^{[1
]}

Nash, Peter ^{[2
]}

Tahir, Hasan ^{[3
]}

Schulze-Koops, Hendrik ^{[4
]}

Li, Lingnan ^{[5
]}

Hojnik, Maja ^{[5
]}

Gellett, Amanda ^{[5
]}

Liu-Leage, Soyi ^{[5
]}

Pillai, Sreekumar ^{[5
]}

Mease, Philip J. ^{[6
,7
]}

机构：

[1] Med Univ Vienna, Vienna, Austria

[2] Griffith Univ, Brisbane, Qld, Australia

[3] Royal Free London NHS Trust, London, England

[4] Ludwig Maximilians Univ Munchen, Dept Rheumatol Clin Immunol, Munich, Germany

[5] Eli Lilly & Co, Indianapolis, IN 46285 USA

[6] Swedish Med Ctr, Seattle, WA USA

[7] Univ Washington, Seattle, WA 98195 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2019年 / 71卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

L20

引用

页数：4

共 50 条

[1] A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM A RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY
Smolen, Josef
Nash, Peter
Tahir, Hasan
Schulze-Koops, Hendrik
Li, Lingnan
Hojnik, Maja
Gellett, Amanda M.
Leage, Soyi Liu
Pillai, Sreekumar G.
Mease, Philip
[J]. INTERNAL MEDICINE JOURNAL, 2020, 50 : 17 - 17
[2] A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAiVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM A RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY
Chaudhury, Sukanya
Gellett, Amanda M.
Hojnik, Maja
Leage, Soyi Liu
Li, Lingnan
Mease, Philip
Nash, Peter
Pillai, Sreekumar G.
Schulze-Koops, Hendrik
Smolen, Josef
Tahir, Hasan
[J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 125 - 125
[3] A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor study
Smolen, Josef
Nash, Peter
Tahir, Hasan
Schulze-Koops, Hendrik
Li, Lingnan
Hojnik, Maja
Gellett, Amanda
Liu-Leage, Soyi
Pillai, Sreekumar
Mease, Philip
Bessette, Louis
[J]. JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1042 - 1042
[4] A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Mease, Philip J.
Smolen, Josef S.
Behrens, Frank
Nash, Peter
Leage, Soyi Liu
Li, Lingnan
Tahir, Hasan
Gooderham, Melinda
Krishnan, Eswar
Liu-Seifert, Hong
Emery, Paul
Pillai, Sreekumar G.
Helliwell, Philip S.
Naftal, Leonardo
Hidalgo, Rodolfo Ariel Pardo
Kerzberg, Eduardo Mario
Savio, Veronica Gabriela
Lazaro, Alicia
Velasco, Benito Jorge
Verzero, Norma Beatriz
Asnal, Cecilia Adma
Mysler, Eduardo Fabian
Berman, Alberto
Ariel, Federico Javier
Rischmueller, Maureen
Zochling, Jane Margaret
Bird, Paul A.
Hall, Stephen
Ostor, Andrew
Romas, Evange
Stummvoll, Georg
Machold, Klaus
Spellitz, Peter
Hanusch, Ursula
Vanden Berghe, Marc
Leon, Marc
Vanhoof, Johan Louis Magda
Van den Bosch, Filip Eduard Jeanne
De Vlam, Kurt Leo Francois
Morin, Frederic
Bessette, Louis
Haaland, Derek A.
Schlemmer, Annette Margrethe
Kristensen, Lars Erik
Jarvinen, Pentti
Peltomaa, Ritva Liisa
Pirila, Laura
Vuotila, Jorma
Lespessailles, Eric
Goupille, Philippe
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (01) : 123 - 131
[5] HEAD-TO-HEAD STUDY EVALUATING THE COMBINED ACR50/PASI100 TREATMENT RESPONSE OF IXEKIZUMAB VERSUS ADALIMUMAB: INDIVIDUAL PATIENT DATA FROM A RANDOMIZED, OPEN-LABEL STUDY IN BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS THROUGH WEEK 52
Kavanaugh, A.
Lubrano, E.
Muram, T.
Lin, C. Y.
Leage, S. Liu
Van den Bosch, F.
Kristensen, L. E.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 763 - 763
[6] SAFETY PROFILES OF IXEKIZUMAB VERSUS ADALIMUMAB: 52-WEEK RESULTS FROM A HEAD-TO-HEAD COMPARISON IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Mease, P. J.
Smolen, J. S.
Kavanaugh, A.
Nash, P.
Gallo, G.
Leage, S. Liu
Sapin, C.
Genovese, M. C.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1698 - 1698
[7] Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis
Mease, Philip
Smolen, Josef
Kavanaugh, Arthur
Nash, Peter
Gallo, Gaia
Liu-Leage, Soyi
Sapin, Christophe
Genovese, Mark
[J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
[8] Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients With Active Psoriatic Arthritis
Mease, Philip
Smolen, Josef
Kavanaugh, Arthur
Nash, Peter
Gallo, Gaia
Liu-Leage, Soyi
Sapin, Christophe
Genovese, Mark
Bessette, Louis
[J]. JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1167 - 1167
[9] MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: 24-WEEK RESULTS
Mease, Philip J.
Smolen, Josef S.
Behrens, Frank
Nash, Peter
Leage, Soyi Liu
Li Lingnan
Tahir, Hasan
Gooderham, Melinda
Krishnan, Eswar
Emery, Paul
Pillai, Sreekumar
Helliwell, Philip
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 261 - 262
[10] SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY
Mcinnes, I.
Behrens, F.
Mease, P. J.
Kavanaugh, A.
Ritchlin, C. T.
Nash, P.
Gratacos-Masmitja, J.
Goupille, P.
Korotaeva, T.
Gottlieb, A. B.
Martin, R.
Ding, K.
Pellet, P.
Mpofu, S.
Pricop, L.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 142 - 143

← 1 2 3 4 5 →